- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1491KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 231KB)
Osimertinib – July 2020
Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso®
Last updated
30 October 2020